These findings are very helpful and suggest the shifting drug targets for HFpEF See more comments To view or add a comment, sign in More Relevant Posts Treatment with semaglutide or tirzepatide was associated with substantially lower risk of hospitalization for heart failure or all-cause mortality compared with sitagliptin acting as a placebo proxy
The biggest cost drivers are prescription pricing, lab repetition, and extra follow-ups during dose titration, so a low advertised rate can rise quickly once add-ons and testing are included
The standard FDA-approved semaglutide protocol uses a once-weekly injection schedule, but emerging evidence and real-world patient experience suggest dosing timing can influence how your body responds to GLP-1 therapy
Qiang Fu, [email protected] These authors have contributed equally to this work and share first authorship Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
In studies patients on tirzepatide lose over 15% of their body weight while taking this medication
Niacinamide at higher doses can cause flushing
